NCT04798612View on ClinicalTrials.gov

Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions
Colon Cancer
Interventions
DRUG

Pegasys

45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between

DRUG

Saline

0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between

Trial Locations (1)

2730

RECRUITING

Herlev University Hospital, Herlev

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

lead

Zealand University Hospital

OTHER